Drug profile · INN
roxadustat
EVRENZO
roxadustat (EVRENZO) is a hypoxia-inducible factor prolyl hydroxylase inhibitor.
EMA: approved PMDA: approved NMPA: clinical trials Blood and blood forming organs (B03) B03XA05
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — roxadustat
- Class
- Blood and blood forming organs (B03)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
roxadustat (EVRENZO) is a hypoxia-inducible factor prolyl hydroxylase inhibitor.
Key facts
INN roxadustat
Brand EVRENZO
Mechanism Hypoxia-inducible factor prolyl hydroxylase inhibitor
Target Hypoxia-inducible factor prolyl hydroxylase
Therapeutic class Blood and blood forming organs (B03)
ATC code B03XA05
Mechanism of action
Hypoxia-inducible factor prolyl hydroxylase inhibitor
Primary target: Hypoxia-inducible factor prolyl hydroxylase
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is roxadustat?
roxadustat (EVRENZO) is a hypoxia-inducible factor prolyl hydroxylase inhibitor.
What is the brand name for roxadustat?
EVRENZO is a marketed brand name for roxadustat. Check FDA Drugs@FDA for the current US label holder and prescribing information.